BrianJayDrukerMD

Oncology • Portland, OR

Hematologic Oncology

Professor of Medicine, Oregon Health & Sci University

Join to view full profile

Dr. Druker is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Druker's full profile

Already have an account?

Office
3181 Sw Sam Jackson Park Rd, L952
Portland, OR 97239
Phone+1 503-494-5596

Fax+1 503-494-3688
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1984 - 1987
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1981 - 1984
University of California San Diego School of MedicineClass of 1981

Certifications & Licensure

OR State Medical License 1993 - 2025
WA State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2007-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Portland Monthly Magazine Castle Connolly, 2011
Elected Member Institute of Medicine, 2003
Elected Member The American Society for Clinical Investigation, 1997
Whos Who in Medicine and Healthcare Marquis Whos Who
Investigator Howard Hughes Medical Institute
Join now to see all

Clinical Trials

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL Start of enrollment: 2014 Apr 24
Completed
Phase 1

Publications & Presentations

PubMed

2 citations
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai, S., Huang, Y., Lance, J., Mao, H., Dunbar, A., McNulty, S., Druley, T., Li, Y., Baer, M., Stock, W., Kovacsovics, T., Blum, W., Schiller, G., Olin, R., Foran, J.,...> ;Blood Advances. 2024 Jan 23
Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
Paul Piehowski, Tao Liu, Elie Traer, Anupriya Agarwal, Sunil K Joshi, Sara J C Gosline, Jason E McDermott, Brian J Druker, Jeffrey W Tyner, Cristina E Tognon, Karin D ...> ;Annual Review of Pharmacology and Toxicology. 2024 Jan 23
Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.
James C Pino, Camilo Posso, Sunil K Joshi, Michael Nestor, Jamie Moon, Joshua R Hansen, Chelsea Hutchinson-Bunch, Marina A Gritsenko, Karl K Weitz, Kevin Watanabe-Smit...> ;Cell Reports. Medicine. 2024 Jan 16
3 citations
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.
Christopher A Eide, Stephen E Kurtz, Andy Kaempf, Nicola Long, Sunil Kumar Joshi, Tamilla Nechiporuk, Ariane Huang, Charles A Dibb, Akosha Taylor, Daniel Bottomly, Sha...> ;Blood Cancer Discovery. 2023 Nov 1
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Uma Borate, Fei Yang, Richard Press, Amy S Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C Pavlick, Luke Juckett, Brianna Norris, Taylor Bu...> ;Blood Advances. 2023 Oct 24
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases.
Olivia M Lucero, Ji-Ann Lee, Jenna Bowman, Kara Johnson, Gopal Sapparapu, John K Thomas, Guang Fan, Bill H Chang, Karina Thiel-Klare, Christopher A Eide, Craig Okada, ...> ;Clinical Cancer Research. 2023 Oct 13
The FLT3mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Sunil K Joshi, Janét Pittsenbarger, Vanessa E Kennedy, Cheryl A C Peretz, Alexander E Perl, Catherine C Smith, Jeffrey W Tyner, Brian J Druker, Elie Traer> ;American Journal of Hematology. 2023 Dec 1
2 citations
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
Giovanni Paolo Maria Zambrotta, Franck E Nicolini, Sarit Assouline, Lambert Busque, Ester Pungolino, Elisabetta Abruzzese, Maria Cristina Miggiano, Chiara Elena, Alber...> ;American Journal of Hematology. 2023 Nov 1
1 citations
Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.
William M Yashar, Brittany M Curtiss, Daniel J Coleman, Jake VanCampen, Garth Kong, Jommel Macaraeg, Joseph Estabrook, Emek Demir, Nicola Long, Daniel Bottomly, Shanno...> ;Molecular Cancer Research. 2023 Jul 5
4 citations
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Antoine N Saliba, Scott H Kaufmann, Eytan M Stein, Prapti A Patel, Maria R Baer, Wendy Stock, Michael Deininger, William Blum, Gary J Schiller, Rebecca L Olin, Mark R ...> ;Blood Advances. 2023 Jun 13
22 citations
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.
Curtis A Lachowiez, Nicola Long, Jennifer Saultz, Arpita Gandhi, Laura F Newell, Brandon Hayes-Lattin, Richard T Maziarz, Jessica Leonard, Daniel Bottomly, Shannon McW...> ;Blood Advances. 2023 May 9
1 citations
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Vu H Duong, Amy S Ruppert, Alice S Mims, Uma Borate, Eytan M Stein, Maria R Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L Arellano, Gary J Schiller, Reb...> ;Cancer. 2023 Aug 1
1 citations
Oncoproteomic profiling of AML: moving beyond genomics.
Sunil K Joshi, Cristina E Tognon, Brian J Druker, Karin D Rodland> ;Expert Review of Proteomics. 2023 Feb 10
2 citations
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
Jerald P Radich, Matthew Wall, Susan Branford, Catarina D Campbell, Shalini Chaturvedi, Daniel J DeAngelo, Michael Deininger, Justin Guinney, Andreas Hochhaus, Timothy...> ;Haematologica. 2023 Jun 1
Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors.
Theodore P Braun, Joseph Estabrook, Zachary Schonrock, Brittany M Curtiss, Lucie Darmusey, Jommel Macaraeg, Trevor Enright, Cody Coblentz, Rowan Callahan, William Yash...> ;Leukemia. 2023 Feb 1
4 citations
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism.
Mayra A Gonzalez, Idaly M Olivas, Alfonso E Bencomo-Alvarez, Andres J Rubio, Christian Barreto-Vargas, Jose L Lopez, Sara K Dang, Jonathan P Solecki, Emily McCall, Gon...> ;Clinical and Translational Medicine. 2022 Dec 1
5 citations
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.
Evan J Barnes, Christopher A Eide, Andy Kaempf, Daniel Bottomly, Kyle A Romine, Beth Wilmot, Dominick Saunders, Shannon K McWeeney, Cristina E Tognon, Brian J Druker> ;British Journal of Haematology. 2023 Feb 1
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia.
Mara W Rosenberg, Samantha L Savage, Christopher A Eide, Anna Reister Schultz, Rachel J Cook, Richard D Press, Carole Rempfer, Garrett Eickelberg, Beth Wilmot, Shannon...> ;Cold Spring Harbor Molecular Case Studies. 2022 Oct 1
13 citations
Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
Sarah A Carratt, Garth L Kong, Brittany M Curtiss, Zachary Schonrock, Lauren Maloney, Breanna N Maniaci, Hunter Z Blaylock, Adrian Baris, Brian J Druker, Theodore P Br...> ;Blood. 2022 Aug 11
63 citations
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.
Daniel Bottomly, Nicola Long, Anna Reister Schultz, Stephen E Kurtz, Cristina E Tognon, Kara Johnson, Melissa Abel, Anupriya Agarwal, Sammantha Avaylon, Erik Benton, A...> ;Cancer Cell. 2022 Aug 8
9 citations
Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.
Gosline, S., Tognon, C., Nestor, M., Joshi, S., Modak, R., Damnernsawad, A., Posso, C., Moon, J., Hansen, J., Hutchinson-Bunch, C., Pino, J., Gritsenko, M., Weitz, K.,...> ;Clinical Proteomics. 2022 Jul 27
4 citations
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.
William G Rice, Stephen B Howell, Hongying Zhang, Nasrin Rastgoo, Andrea Local, Stephen E Kurtz, Pierrette Lo, Daniel Bottomly, Beth Wilmot, Shannon K McWeeney, Brian ...> ;Molecular Cancer Therapeutics. 2022 Jul 5
1 citations
Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.
Theodore P Braun, Mariam Okhovat, Cody Coblentz, Sarah A Carratt, Amy Foley, Zachary Schonrock, Brittany M Curtiss, Kimberly Nevonen, Brett Davis, Brianna Garcia, Dori...> ;Nature Communications. 2022 Jun 16
4 citations
PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
Brittany M Curtiss, Jake VanCampen, Jommel Macaraeg, Garth L Kong, Akram Taherinasab, Mitsuhiro Tsuchiya, William M Yashar, Yiu H Tsang, Wesley Horton, Daniel J Colema...> ;Leukemia. 2022 Jul 1
18 citations
Understanding Drug Sensitivity and Tackling Resistance in Cancer.
Jeffrey W Tyner, Franziska Haderk, Anbarasu Kumaraswamy, Linda B Baughn, Brian Van Ness, Song Liu, Himangi Marathe, Joshi J Alumkal, Trever G Bivona, Keith Syson Chan,...> ;Cancer Research. 2022 Apr 15
Join now to see all

Journal Articles

CRISPR-Cas9–Mediated Saturated Mutagenesis Screen Predicts Clinical Drug Resistance with Improved Accuracy
Richard D Press, Brian J Druker, Michael R Green, Proceedings of the National Academy of Sciences

Press Mentions

Internationally Renowned OHSU Cancer Biologist Elected to the National Academy of SciencesMay 2nd, 2023
The Immaculate Conception of Gleevec, as Told by Brian DrukerApril 25th, 2023
University of Oregon Helmet Auction Raises over $66,000 for OHSU Breast Cancer ResearchOctober 26th, 2022
Join now to see all

Grant Support

Chronic Myelogenous Leukemia And BCR-ABL SubstratesNational Cancer Institute2011–2012
Senior LeadershipNational Cancer Institute2011
Protocol Specific Research SupportNational Cancer Institute2011
Protocol Review &Monitoring SystemNational Cancer Institute2011
Proteomics Shared ResourceNational Cancer Institute2011
Program Planning And EvaluationNational Cancer Institute2011
Program LeadershipNational Cancer Institute2011
Histapathology &Cancer Genotyping Shared ResourceNational Cancer Institute2011
Flow Cytometry Shared ResourceNational Cancer Institute2011
Developmental FundsNational Cancer Institute2011
Data Safety Monitoring SystemsNational Cancer Institute2011
Clinical Research Management Shared ResourceNational Cancer Institute2011
Bioanalytical/Pharacokinetic Shared ResourceNational Cancer Institute2011
AdministrationNational Cancer Institute2011
Ohsu Knight Cancer InstituteNational Cancer Institute2009–2011
Ohsu Knight Cancer Institute- Community Health Educator SupplementNational Cancer Institute2010
Ohsu Knight Cancer Institute - Rapid SupplementNational Cancer Institute2010
Accelerating Target Identification And Validation In Leukemia: Integrating Sirna-National Cancer Institute2009–2010
Chronic Myelogenous Leukemia And BCR-ABL SubstratesNational Cancer Institute1995–2009
Ohsu Cancer InstituteNational Cancer Institute2007–2008
Cancer And KinasesNational Cancer Institute2005
CBL Function In Cellular Signaling And TransformationNational Cancer Institute1999–2003
Tyrosine Kinase Inhibitors As Antineoplastic AgentsNational Cancer Institute1999–2001
Genetic Analysis Of The Activation Of A Tyrosine KinaseNational Cancer Institute1993–1994
Genetic Analysis Of The Activation Of A Tyrosine KinaseNational Cancer Institute1990–1992
Mutagenesis Of Polyoma Middle-T AntigenNational Cancer Institute1986